Ian Conner is an Ophthalmology physician affiliated with University of Pittsburgh. OpenAlex indexes 80 publications with 1,278 citations (h-index 20); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
203 Lothrop St
Eei 7th Floor
Pittsburgh, PA 152132548
Telephone
412-647-2200Registry record last updated 25 Mar 2021.
Clinical trials
- Acetazolamide for Treatment Resistant Schizophrenia
Sponsor: Vishwajit Nimgaonkar, MD PhD
- Novel Diagnostics With Optical Coherence Tomography: Imaging the Anterior Eye
Sponsor: NYU Langone Health
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
12 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Alcon Vision LLCProgram year202512 payments$31,265openpaymentsdata.cms.gov ↗
- NEW WORLD MEDICAL,INC.Program year20258 payments
- ABBVIE INC.Program year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
82.2%Prostaglandin Analog30.4%Latanoprost73%Lumigan20%Travoprost4%Iyuzeh1%Xalatan1%Bimatoprost1%Travatan Z1%Part D<11 patientsCarbonic Anhydrase Inhibitor24.6%Dorzolamide-Timolol64%Dorzolamide Hcl24%Simbrinza5%Brinzolamide4%Cosopt Pf2%Acetazolamide Er2%Part D<11 patients+ 7 more classes in this area
Cardiovascular
10.1%Beta blocker10.1%Timolol Maleate98%Timoptic Ocudose2%Part D<11 patientsAnti-infectives
2.9%Fluoroquinolone Antibacterial1.6%Moxifloxacin100%Part D≥54 patientsMacrolide0.7%Erythromycin100%Part D≥17 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Norman Wolmark, MD
University of Pittsburgh
Sally Wenzel, MD
University of Pittsburgh
Mary Phillips, MD
University of Pittsburgh
Udai Kammula, MD
University of Pittsburgh
Emily Chew, MD
National Eye Institute
Robert Weinreb, MD
University of California San Diego
Harry Quigley, MD
Johns Hopkins University School of Medicine
Joel Schuman, MD
Wills Eye Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”